{
    "Trade/Device Name(s)": [
        "ImmunoCard C. difficile GDH",
        "ImmunoCard\u2122 C. difficile GDH Assay"
    ],
    "Submitter Information": "Meridian Bioscience, Inc.",
    "510(k) Number": "K112048",
    "Predicate Device Reference 510(k) Number(s)": [
        "K053572"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "MCB"
    ],
    "Summary Letter Date": "December 7, 2011",
    "Summary Letter Received Date": "December 8, 2011",
    "Submission Date": "November 29, 2011",
    "Regulation Number(s)": [
        "21 CFR 866.2660"
    ],
    "Regulation Name(s)": [
        "Microorganism Differentiation and Identification Device"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Clostridium difficile glutamate dehydrogenase antigen"
    ],
    "Specimen Type(s)": [
        "Fecal specimens",
        "Human stool",
        "Solid stool",
        "Semi-solid stool",
        "Liquid stool",
        "Bloody stool",
        "Watery stool"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Visual read"
    ],
    "Methodologies": [
        "Rapid qualitative enzyme immunoassay",
        "Screening test"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for ImmunoCard C. difficile GDH rapid qualitative EIA for detection of C. difficile GDH antigen in human stool",
    "Indications for Use Summary": "Rapid qualitative enzyme immunoassay screening test to detect Clostridium difficile glutamate dehydrogenase antigen in fecal specimens from persons suspected of having C. difficile infection; does not distinguish between toxigenic and non-toxigenic strains and positive results require further testing for toxigenic strains.",
    "fda_folder": "Microbiology"
}